Raymond James Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with an Outperform rating and set a price target of $18.
July 25, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has initiated coverage on ARS Pharmaceuticals with an Outperform rating and set a price target of $18.
The initiation of coverage with an Outperform rating and a price target of $18 by a reputable analyst at Raymond James is likely to positively impact the stock price of ARS Pharmaceuticals in the short term. This rating suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100